LIST OF CLAIMS

1. (Previously Presented) A compound represented by the following formula (I), a pharmacologically acceptable salt thereof or hydrates thereof:

$$\begin{array}{c|c}
R^1 & A & R^4 \\
 & R^5 \\
 & N & O \\
 & R^2
\end{array} \tag{I}$$

wherein A represents oxygen; R¹ represents a phenyl having an N,N-di-lower alkylaminoalkoxy group or morpholinyl-lower alkoxy group, pyridyl group or a pyridyl group having a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group; R² represents a phenyl, a phenyl having a halogen atom, a pyridyl group or a pyridyl having a nitril group; and R⁴ and R⁵ each represents a hydrogen atom.

2-12. (Canceled)

13. (Previously Presented) A pharmaceutical composition comprising a pharmacologically acceptable amount of the compound represented by the following formula (I), a pharmaceutically acceptable salt thereof or hydrates thereof, and pharmacologically acceptable carriers:

$$\begin{array}{c|c}
R^1 & A & R^4 \\
N & & R^5 \\
N & & O \\
R^2 & & &
\end{array} (1)$$

wherein A represents oxygen; R^1 is a phenyl having an N, N-dilower alkylaminoalkoxy group or morpholinyl-lower alkoxy group, pyridyl group or a pyridyl group having a halogen atom, hydroxy group, a lower alkyl group or a lower alkoxy group; R^2 is a phenyl, a phenyl having a halogen atom, a pyridyl group or a pyridyl having nitril group; and R^4 and R^5 each represents a hydrogen atom.

14-25. (Canceled)

26. (Currently Amended) A method of treating and ameliorating acute nerve degeneration after cerebral ischemia, traumas in the head and spinal injuries, epilepsy, or pain, multiple sclerosis, encephalomyelitis, Guillain Barre syndrome, Devic disease, Balo disease, which comprises comprising administering a pharmacologically effective amount of the pharmaceutical preparation according to claim 13 to a patient.

27-33. Canceled.

34. (Previously Presented) A compound selected from the group consisting of 2-(2-Pyridyl)-4-phenyl-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-(2-pyridyl)-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one, 2-(2-Pyridyl)-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one, 2-Phenyl-4-(2-cyano-3-pyridyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-[2-(2-Dimethylamino)ethoxyphenyl]-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-[2-(2-dimethylaminoethoxy)phenyl]-4-phenyl-4 H-1,3,4-oxadiazine-5(6H)-one hydrochloride, 2-[2-(2-Dimethylaminoethoxy)phenyl]-4-(2-fluorophenyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride, and 2-{2-[2(4-Morpholinyl)ethoxyphenyl}-4-(2-bromophenyl)-4H-1,3,4-oxadiazine-5(6H)-one hydrochloride.